On July 7, 2026 VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, reported the release of a new clinical study demonstrating the significant prognostic value of its Nu.Q Cancer Assay in newly diagnosed lung cancer patients, which could help clinicians identify patients’ likely outcomes and personalize treatment selection accordingly. The clinical paper entitled "Prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients: Real-world evidence1" has been written in conjunction with researchers and clinicians at the Hospices Civils de Lyon (HCL), France’s second largest university hospital system, and is currently under peer review.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Andrew Retter, Medical Consultant, Volition said:

"Nu.Q Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring and is a test we envisage will be used routinely in the clinic once approved.

"We have worked closely with the Lyon team over several years to develop the strong scientific and clinical evidence to support the use of Nu.Q in the management of cancer patients. These results indicate that measuring methylated nucleosome biomarker levels with the Nu.Q test, at Non Small Cell Lung Cancer diagnosis, can provide valuable information about survival, progression-free survival and, crucially, enhance the identification of patients who may benefit from curative care1-4.

"The integration of epigenetic biomarkers, such as circulating H3K27Me3-nucleosome, into personalized medicine frameworks holds great promise for refining patient stratification and treatment selection.

The test is simple to complete and easy to implement, the new information helps to empower bedside clinicians and their patients to make better informed decisions on treatments and planning future care together."

Frederic Wuilque, Vice President, Global Products, added:

"The first step in introducing the Nu.Q Cancer test into routine clinical practice, the clinical certification at HCL, has been completed.
"With the active support of HCL, we are working towards the submission of our reimbursement dossier in the coming months, under the framework of the "Innovative Procedures Outside the Nomenclature" (RIHN-référentiel des actes innovants hors nomenclature). Once the dossier is classified as admissible, we understand that determination of eligibility for reimbursement coverage is mandated to take no more than five months.
"We are delighted to showcase more evidence to demonstrate the clinical utility of our Nu.Q Cancer test and would like to thank our long term collaborator, Hospices Civils de Lyon, for their continued support. We continue to move through the steps on the path to the first use of Nu.Q in clinical practice, an exciting prospect which is core to Volition’s mission, using our tests to help save lives."

Mr. Gael Forterre, Chief Commercial Officer, Volition concluded:

"From a commercial perspective, France is just the beginning: the Volition team is actively discussing Nu.Q Cancer, not only with hospital networks in other countries but also potentially licensing the technology to third party collaborators. For this direct sales model we anticipate approximately €50 per test as revenue to Volition.
"Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q in the human cancer field. Once achieved, we anticipate the introduction into routine clinical use in France."

About the Study

A large, real-world evidence study which demonstrated that plasma levels of Nu.Q Cancer assay H3K27Me3 were associated with cancer stage, and highly elevated levels were observed in patients with a poor outcome.
Overall survival (OS) analysis revealed that patients with a H3K27Me3-nucleosome level below the optimal cut-off had a significantly better mean survival compared to those with higher concentrations, particularly for patients who are ctDNA-negative and therefore lacking detectable actionable mutations.
Interestingly, a Cox Proportional Hazards (CPH) prognostic model, integrating baseline H3K27Me3-nucleosome concentrations with commonly collected clinical covariates (cancer stage, ctDNA molecular profile and age) enabled stratification of patients at diagnosis into low and high risk mortality groups, facilitating prediction of patient-level survival probabilities in a timeline of up to 30 months.

(Press release, VolitionRX, JUL 7, 2026, View Source [SID1234669092])